Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
“Precipio is a microcap specialty cancer diagnostics company offering both molecular assay kits and pathology services. Its core product lines include HemeScreen molecular assays, and IV-Cell Culture media, as well as operating its own clinical laboratory. HemeScreen is a set of proprietary molecular tests for hematologic malignancies (i.e., blood cancers). IV-Cell culture media is a universal cytogenetic culture media used for testing of hematologic cancers (i.e., Leukemia). Both products utilize proprietary chemical assays that have been developed over the years and are kept as trade secrets by the company, providing them protection from anyone trying to copy their products. Precipio's estimated market share remains under 1% of its total addressable market in their current products. Both product end markets are growing within the broader $115B oncology diagnostics market. With the help of their key product distributors, including Thermo Fisher, McKesson, Medline, and Cardinal Health, the company has an excellent path to growth within their current product portfolio and the ability to launch similar new cancer diagnostic products into adjacent markets. The company has been on a multi-year path to get to cashflow and EBITDA breakeven. Through a combination of cost-cutting efforts and scaling efficiencies, they have been able to improve their pathology services gross margins from the mid-20s to the mid-40s over the last 3 years. CEO Ilan Danieli noted in their Q4 2024 results that they are past the point of needing outside capital, saying, “Managing a company that no longer relies on outside capital infusions for its survival enables us to make decisions based on growth and value creation without the constraints imposed by cash conservation concerns.” The last three quarters further underscore their progress toward a positive cash flow, in which in each quarter they generated near zero EBITDA. In the last 2 years there have been two industry-related issues that have negatively impacted their business, which seem to be behind the company. Firstly, there was a hack at Change Healthcare, the country's largest clearinghouse which facilitates the majority of insurance billing nationwide. In February of 2024 that hack caused significant billing and payment delays into late 2024 for most healthcare providers in the country. The company relied on Change Healthcare's temporary funding assistance program in 2024 to help stabilize the company's balance sheet. This hack was resolved in late 2024, and the cash flow from payors that Precipio relies on has been fully restored. Secondly, in late 2024, the FDA provided a final rule regulating laboratory development tests (LDTs) as medical devices, which could have negatively impacted the entire diagnostic field's regulatory requirements by imposing extremely stringent, complex and costly regulations on laboratories in the US. This caused significant uncertainty among laboratories as to their ability to purchase assays such as HemeScreen, and as a result, many laboratories placed on hold all efforts to explore new products, impacting Precipio's Products Division growth. The rule was struck down in Q1 by a federal court in Texas, which vacated the rule, making it no longer legally binding. This uncertainty in the industry has been lifted from the company, and shortly after, Precipio saw numerous laboratories resume their interest in the company's products. Precipio currently has "going concern" language in their financial audit due to recurring operating losses and concerns about its ability to meet financial obligations without raising additional capital. This language reflected historical cash burn and uncertainty exacerbated by external disruptions such as the Change Healthcare cyberattack and the FDA ruling. However, in its most recent quarters, the company has demonstrated a meaningful shift toward financial stability, reporting positive operating cash flow and significantly improved revenue performance. On a recent call I had with the company's CEO, Ilan Danieli, he expressed a belief that continued cash flow positivity, combined with cost controls and increased customer demand, strengthens Precipio's financial position and will likely lead to the removal of the going concern language in upcoming filings. BSD Analysis: Precipio offers a high-upside asymmetric setup: a niche oncology diagnostics company nearing cash-flow breakeven with accelerating gross margin expansion and recently resolved external headwinds. Its proprietary HemeScreen assays and IV-Cell media create defensible IP-driven moats, while distributor partnerships provide scalable commercial reach. MolDx approval unlocks ~$1M of near-100% gross margin revenue, materially improving cash generation. At ~1× EV/revenue, the valuation sits far below diagnostics peers (3–10×), leaving substantial re-rating potential as breakeven is achieved and “going concern” language is removed. Key catalysts include continued pathology volume growth, additional panel adoption, and institutional ownership once financials stabilize.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
